openPR Logo
Press release

Lymphoma Treatments Market To Reflect Impressive Growth Rate During 2023

01-22-2018 10:50 AM CET | Health & Medicine

Press release from: Transparency Market Research

Lymphoma Treatments Market To Reflect Impressive Growth Rate

Lymphoma is a kind of blood cancer which occurs when B or T lymphocytes and leukocytes grow abnormally. In addition, it also occurs if these cells survive longer than their normal life cycle. Lymphoma generally occurs in lymph nodes, bone marrow, spleen, blood and other organs which form a part of the lymphatic system. Lymphoma is of two types namely hodgkin and non-hodgkin. Hodgkin lymphoma develops in the lymph nodes of the lymphatic system. Non-Hodgkin lymphoma is the most common type of lymphoma and develops in related tissues of the lymphatic system and lymph nodes. The common symptoms of lymphoma are swelling of lymph nodes, fever, weight loss, night sweets, anorexia, itching, dyspnoea and fatigue. The common tests applied for the diagnosis of lymphoma are immunophenotyping, FISH (Fluorescence in Situ Hybridization) testing and flow cytometry. Radiation therapy, chemotherapy and monoclonal antibody therapy are performed on the patients suffering from lymphoma. Among all these treatment options, the most common method to treat lymphoma is chemotherapy.

Since chemotherapy destroys the cancer cell by obstructing its division process, it acts as one of the key method for Lymphoma Treatment. These medicines travel throughout the body while during the course of medication. Various drugs that are used for the treatment of lymphoma include Adcertis (brentuximab), Arranon (nelarabine), Adriamycin (doxorubicin), Decadron (dexamethasone), Baycadron (dexamethasone), Deltasone (prednisone), Dexamethasone Intensol (dexamethasone), Dexpak Taperpak (dexamethasone) and Folotyn (pralatrexate). Other drugs used include Prednicot (prednisone), Roferon-A (interferon alfa-2a), Solurex (dexamethasone), Leukeran (chlorambucil), Zema Pak (dexamethasone), Velcade (bortezomib), Sterapred DS (prednisone), Thioplex (thiotepa), Velban (vinblastine) and Trexall (methotrexate).

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1396

Rise in the incidence of lymphoma throughout the globe is expected to drive the growth of lymphoma treatments market. According to the Leukemia and Lymphoma Society, in 2012, around 700,000 people suffered from lymphoma in Canada alone. The government of various nations such as the U.S. and Europe has amplified their funding in R&D for the development of lymphoma treating drugs which would further augment the growth of lymphoma treatments market. Moreover, they have started many programs for patient awareness about lymphoma and its treatments. Despite all these advantages, various side effects of chemotherapy would hamper the growth of lymphoma treatments market. These side effects include hair loss, nausea, vomiting and fatigue. In addition, high cost of this treatment may also hamper the growth of lymphoma treatments market. Moreover, few nations such as the U.K are not providing reimbursement for every lymphoma treating drug which may also hamper its growth lymphoma treatments market.

In 2013, North America accounted for the largest share of global lymphoma treatments market. This is due to the fact that most of the key players who are engaged in developing and manufacturing lymphoma treating drugs are domiciled in the region. In addition, favorable government funding in the region has also contributed heavily in capturing the largest revenue share. During the forecast period 2014 to 2020, Asia-Pacific is expected to grow at the highest CAGR owing to rising incidences of lymphoma in the countries such as China, Malaysia and India. In addition, increasing disposable income coupled with rising healthcare expenditure would further accentuate the growth of lymphoma treatments market in the region. Major players operating in lymphoma treatments market include Abbott Laboratories, Eli Lilly and Company, Bristol-Myers Squibb Company, ABIOGEN PHARMA S.p.A., Johnson & Johnson, Aeterna Zentaris, Inc. and Merck & Co., Inc. among other significant players across the globe.

Pre-Book Full Report -

https://www.transparencymarketresearch.com/checkout.php?rep_id=1396<ype=S

About Us
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lymphoma Treatments Market To Reflect Impressive Growth Rate During 2023 here

News-ID: 910755 • Views: 123

More Releases from Transparency Market Research

Market Intelligence Report on Calcite Market, 2018-2028
Sales of calcite have witnessed utter proliferation in recent time, in line with the growing demand from paper and pulp sector wherein calcite is highly adopted as a coating and filler material. According to Transparency Market Research analysis, global calcite market is anticipated to register 4.7% CAGR during the study period 2018–2028. The TMR report opines that demand for calcite is highly driven by its significant properties that are paving way
Pearlescent Pigments Market Intelligence Report Offers Growth Prospects
The demand within the global pearlescent pigment market is slated to rise as new creative avenues emerge in the art and craft industry. Several artists have increased the consumption of pearlescent pigments, mainly due to the aesthetic value of these pigments in art forms. The use of these pigments can majorly be attributed to the gloss and shine imparted by these pigments to the design or craft. These pigments exhibit
Aragonite Market to Witness Steady Growth During the Forecast Period 2018-2026
Global Aragonite Market: Overview Aragonite is a carbonate mineral having an orthorhombic crystal system, and very closely resembles calcite. It is considered as the purest form of calcium carbonate. The mineral has garnered wide popularity as gemstone in various parts of the world and has promising healing properties with energy enhancing powers. Aragonite contains traces of magnesium and sand inclusion but rich in calcium carbonate, and is alkaline in nature. It
OEM Insulation Market Growth, Trends and Value Chain 2019-2027 by TMR
OEM Insulation Market – Overview OEM means Original Equipment Manufacturer that indicates to a company that produces a part or a subsystem of a product that is being used by another organization. Thermal insulation or simply insulation allows the product to cut down the heat gain or loss at the minimum by creating a barrier between the surfaces at the varying temperatures. There are wide range of applications and end-use verticals

All 5 Releases


More Releases for Lymphoma

Lymphoma Drugs Market Growth 2019-2024
According to 24 Market Reports study, over the next five years the Lymphoma Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. Lymphoma is cancer that begins in infection-fighting cells of the immune system, called lymphocytes. These cells are in the lymph nodes, spleen, thymus, bone marrow, and other parts of the
Lymphoblastic Lymphoma Market : Overview and Analysis
Lymphoblastic lymphoma involves both T-lymphocytes and B-lymphocytes, of which 84% to 90% cases of lymphoblastic lymphoma involve T-lymphocytes. Chemotherapy is the preferred choice and first line treatment in cases of lymphoblastic lymphoma, where the regimen is followed for the treatment and includes induction chemotherapy, consolidation chemotherapy, and continuing chemotherapy. Other treatments include radiotherapy which might be given in the brain or spine if lymphoma cells are present or in other
Burkitt Lymphoma Therapeutics Market Key Growth Drivers
Burkitt lymphoma is a form of non-Hodgkin's lymphomas (NHLs) which are a group of blood cancers derived from lymphocytes. Burkitt lymphoma is a rare disease and occurs only in one in every 30-50 people with non-Hodgkin's lymphomas. According to the World Health Organization (WHO), Burkitt lymphomas are of three types, namely, endemic, sporadic and immunodeficiency associated. Endemic NHL is also known as African type and affects African children aged between
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape. Hodgkin disease is a cancer of the lymphatic system. It
Lymphoma Therapeutics Market Report : 2017
Reports And Markets Publish a New Market Research Report On –"Lymphoma Therapeutics Market Report 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/united-states-lymphoma-therapeutics-market-report-2017-1541149 In this report, the United States Lymphoma Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. T-Cell Lymphoma Market Analysis 2. Mechanism of T-Cell Lymphoma Therapeutics 3. T-Cell Lymphoma Drug Market Overview 3.1 Current Market Scenario 3.2 T Cell Lymphoma Clinical Pipeline Overview 4. T-Cell Lymphoma Drug Market Dynamics 4.1 Favorable Market Parameters 4.2 Commercialization Challenges 5. T-Cell Lymphoma Drug Market Future Prospects 6. T-Cell Lymphoma Drug Clinical Pipeline By Company